Last reviewed · How we verify
HZ/su vaccine GSK1437173A
HZ/su vaccine GSK1437173A is a Recombinant subunit vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of post-herpetic neuralgia in adults aged 50 years and older.
This recombinant zoster vaccine stimulates immune responses against varicella-zoster virus (VZV) to prevent herpes zoster (shingles) and post-herpetic neuralgia in older adults.
This recombinant zoster vaccine stimulates immune responses against varicella-zoster virus (VZV) to prevent herpes zoster (shingles) and post-herpetic neuralgia in older adults. Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of post-herpetic neuralgia in adults aged 50 years and older.
At a glance
| Generic name | HZ/su vaccine GSK1437173A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Recombinant subunit vaccine |
| Target | Varicella-zoster virus glycoprotein E (VZV gE) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
GSK1437173A is a subunit vaccine containing recombinant VZV glycoprotein E (gE) combined with the AS01B adjuvant system, which enhances both cellular and humoral immune responses. The vaccine primes T-cell and B-cell immunity against VZV, reducing the risk of reactivation and the severity of herpes zoster disease in immunocompetent older populations.
Approved indications
- Prevention of herpes zoster (shingles) in adults aged 50 years and older
- Prevention of post-herpetic neuralgia in adults aged 50 years and older
Common side effects
- Injection site erythema
- Injection site pain
- Myalgia
- Fatigue
- Headache
Key clinical trials
- A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant (PHASE1, PHASE2)
- A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults (PHASE3)
- Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster (PHASE3)
- A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response (PHASE3)
- Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older (PHASE3)
- Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older (PHASE3)
- Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age (PHASE3)
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HZ/su vaccine GSK1437173A CI brief — competitive landscape report
- HZ/su vaccine GSK1437173A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about HZ/su vaccine GSK1437173A
What is HZ/su vaccine GSK1437173A?
How does HZ/su vaccine GSK1437173A work?
What is HZ/su vaccine GSK1437173A used for?
Who makes HZ/su vaccine GSK1437173A?
What drug class is HZ/su vaccine GSK1437173A in?
What development phase is HZ/su vaccine GSK1437173A in?
What are the side effects of HZ/su vaccine GSK1437173A?
What does HZ/su vaccine GSK1437173A target?
Related
- Drug class: All Recombinant subunit vaccine drugs
- Target: All drugs targeting Varicella-zoster virus glycoprotein E (VZV gE)
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of herpes zoster (shingles) in adults aged 50 years and older
- Indication: Drugs for Prevention of post-herpetic neuralgia in adults aged 50 years and older
- Compare: HZ/su vaccine GSK1437173A vs similar drugs
- Pricing: HZ/su vaccine GSK1437173A cost, discount & access